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Abstract
Heparin-induced thrombocytopenia (HIT I) is a severe, life-threatening, and immuno-
logical drug reaction. According to the clinical-laboratory characteristics, there are two 
types of HIT: type I (HIT I) and type II (HIT II). HIT I is the result of non-immunologic, 
direct interaction of heparin with the platelet surface. Contrary, HIT II is immunologi-
cally induced (antibody-mediated) and life-threatening side effect of heparin therapy, 
often associated with thromboembolic complications. All patients receiving heparin are 
exposed to the development of anti-heparin antibodies, irrespective of the heparin dos-
age, type, and method of administration. HIT most commonly develops in intensive care 
patients, dialyzed patients, and cardiosurgical and orthopedic patients. It commonly 
develops after 5–10 days of heparin therapy. Platelet count decreases by more than 50% 
from the baseline and ranges from 20 × 109/L to 100 × 109/L. In HIT II, thromboembolic 
complications usually include deep-vein thrombosis and pulmonary embolism, but 
they also include arterial occlusion of the extremities, myocardial infarction, stroke, and 
necrosis and organ damage. Clinical assessment of the HIT probability using 4T´s score 
system, systematic monitoring of platelet number in heparin-receiving patients, and 
specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the 
final confirmation of the diagnosis, enable timely administration of direct non-heparin 
thrombin antagonists, and reduce mortality from thromboembolic complications.
Keywords: heparin, heparin-induced thrombocytopenia (HIT), HIT type I, HIT type II, 
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1. Introduction
Heparin-induced thrombocytopenia type II (HIT II) is a severe, life-threatening, immunological 
drug reaction. HIT II is an important side effect of heparin, the most commonly used antico-
agulant agent. As opposed to bleeding caused by heparin overdose, some patients develop a 
paradoxical complication of heparin treatment – thromboembolism. According to the clinical-
laboratory characteristics, there are two types of HIT: type I (HIT I) and type II (HIT II). HIT 
I is the result of non-immunologic, direct interaction of heparin with the platelet surface. It 
occurs in approximately 10% of the patients in the first several days of heparin treatment. 
Thrombocytopenia is mild and resolves within several days with the continuation of heparin 
therapy. Thromboembolic complications usually do not occur; therefore, it is of minor clini-
cal significance. Contrary, HIT II is immunologically induced (antibody-mediated) and a life-
threatening side effect of heparin therapy, often associated with thromboembolic complications 
[1]. The HIT may occur during the treatment with unfractionated heparin (UFH) or low-molec-
ular-weight heparin (LMWH). All patients receiving heparin are exposed to the development 
of anti-heparin antibodies, irrespective of heparin dosage (prophylactic or therapeutic), type 
(UFH or LMWH), and method of administration (subcutaneous or intravenous). Since hepa-
rin is also used for flushing intravenous lines, it may lead to the development of anti-heparin 
antibodies in patients who do not receive subcutaneous or intravenous heparin [1, 2]. HIT 
most often develops in intensive care patients, hemodialyzed patients, and cardiosurgical and 
orthopedic patients, who usually receive heparin. Heparin-induced thrombocytopenia (HIT) is 
a clinical-pathologic syndrome diagnosed based on clinical findings and laboratory evidence 
of antibodies directed to the heparin and platelet factor 4 complex (H-PF4). HIT II may also be 
defined as a transitory, autoimmune, and heparin-induced thrombocytopenia. Reaching the 
diagnosis of HIT is a complex process, because thrombocytopenia in patients receiving heparin 
may be caused by numerous other factors. Although clinical assessment is very important in 
suspecting HIT, laboratory diagnosis plays the key role in providing evidence for the diagno-
sis of HIT II [3–5]. HIT II occurs in 0.1–5.0% heparin-treated patients, predominantly in those 
receiving UFH. It commonly develops after 5–10 days of therapy, but it may also occur earlier 
during the treatment course if the patient has been exposed to heparin within the previous 
100 days (early form). HIT II rarely develops after 20 or more days from the start of the therapy 
(late form). In HIT II, platelet count decreases by more than 50% from the baseline and ranges 
from 20 × 109/L to 100 × 109/L. HIT II patients are at high-risk of thromboembolic complica-
tions, venous and/or arterial, and allergic reactions. In HIT II, thromboembolic complications 
usually include deep-vein thrombosis and pulmonary embolism, but they also include arterial 
occlusion of the extremities, myocardial infarction, stroke, and necrosis and organ damage. 
Vein thrombosis may be found by duplex ultrasound in more than 50% of the patients with no 
clinical signs or symptoms of thrombosis [1–4]. In one-fourth of the HIT II patients, an allergic 
reaction may develop within 5–30 min after intravenous heparin administration (fever, chills, 
and respiratory distress). Rarely, an erythematous plaque or necrosis with pronouncedly pain-
ful skin may be observed. Complications related mortality rate was high (20–30%), but it has 
been significantly reduced in recent years due to the early diagnosis and treatment of HIT with 
heparin alternative [5, 6].
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1.1. Heparin
Heparin is a polymer of varying chain size. Two forms of heparin are used as paharmaceu-
ticals: unfractionated heparin (UFH) that has not been fractionated to sequester the frac-
tion of molecules with low molecular weight, and low molecular weight heparin (LMWH), 
which undergone fractionation. Either UFH or LMWH can be used in the prevention of 
thromboembolic events LMWH is preferable. Heparin binds to the enzyme inhibitor anti-
thrombin III (AT) via a specific pentasaccharide sulfation sequence contained within the 
heparin polymer. The formation of a ternary complex between AT, thrombin, and heparin 
results in the inactivation of thrombin, factor Xa, and other proteases. In contrast, anti-
factor Xa activity requires only the pentasaccharide binding site. The highly negative charge 
density of heparin contributes to its very strong electrostatic interaction with thrombin. For 
this reason, heparin’s activity against thrombin is size-dependent, with the ternary complex 
requiring at least 18 saccharide units for efficient formation. The rate of inactivation of these 
proteases by AT can increase by up to 1000-fold due to the binding of heparin. The size dif-
ference of heparin has led to the development of low-molecular-weight heparins (LMWHs) 
and, more recently, to fondaparinux as pharmaceutical anticoagulants. Fondaparinux is a 
synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding 
pentasaccharide sequence that can be found within polymeric heparin and heparan sulfate. 
LMWHs and fondaparinux target anti-factor Xa activity rather than AT activity, with the 
aim of facilitating a more suitable regulation of coagulation and an improved therapeutic 
index [6].
2. Pathophysiology
The pathophysiologic mechanism of HIT II is mediated by the formation of heparin-platelet 
factor 4 (PF4) complexes. The PF4 is a positively charged heterodimer found in platelet alpha 
granules, and heparin is a negatively charged molecule. The formation of heparin-PF4 com-
plex results in the change in the tertiary structure of the PF4 and exposure of neo-peptide, 
which elicits the formation of antibodies, usually IgG isotype. The immune heparin-PF4-IgG 
complexes activate platelets via Fc y IIa receptors. The antibodies may bind to monocytes, 
which then release tissue factor, the most potent blood clotting factor. Activated platelets 
release procoagulant microparticles and PF4. Antibodies recognize the complexes, bind to the 
endothelial cells, and activate the coagulation cascade, which leads to the formation of throm-
bin and eventually thrombosis. The ability of HIT antibodies to strongly activate platelets 
even in the absence of heparin may cause heparin-independent HIT II [7–9].
HIT II is most often caused by IgG antibodies targeting heparin-PF4 complex. In patients with 
HIT antibodies present in the blood, re-administration of heparin causes a rapid decrease 
in the platelet counts (within hours) to extremely low values. In heparin-treated patients, 
platelet count should be monitored before and during therapy. Before the specific laboratory 
evidence of anti-heparin antibodies, the probability of HIT should be determined using clini-
cal laboratory indicators.
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3. Clinical diagnosis
Clinicians should assess whether the platelet count decrease is the result of anti-heparin anti-
bodies or underlying disease. They should also be cautious not to over diagnose HIT, because 
some HIT antibodies are not pathogenic and will not necessarily lead to the clinical HIT syn-
drome. Before the specific laboratory evidence of anti-heparin antibodies, the probability of 
HIT should be determined using clinical-laboratory indicators. In heparin-treated patients, 
platelet count should be monitored before and during the course of therapy. According to the 
2006 British Haematology Standards, platelet count should be determined in all patients on 
the day of the start of heparin therapy. In patients who received heparin within the previous 
100 days, platelet count should be determined on the day of the start of heparin therapy and 
24 h later. In patients receiving UFH, platelet count should be measured daily from day 4 to 
day 14, and every 2–4 days between day 4 and day 14 in patients receiving LWMH [10–13].
The clinical scoring system used for determining the probability of a HIT is the so-called “4 T 
score” - thrombocytopenia, timing of onset, thrombosis, and absence of other causes of throm-
bocytopenia (Table 1) [6]. Each of these symptoms is scored from 0 to 2 points. The total score 
of 0–3 indicates a low probability of HIT II, 4–5 indicates moderate, and 6–8 indicates a high 
4Ts Score
T1
Thrombo-cytopenia
(a) Platelet count decline by >50%, with lowest value of 20 × 10/9/L 2
(b) Platelet count by 30–50%, with lowest value of 10–19 × 10/9/L 1
(c) Platelet count decline by <30%, with lowest value below 10 × 10/9/L 0
T2
Timing od platelet count 
decline
(a) Occurrence of thrombocytopenia 5–10 days of initial heparin 
administration or <1 day (with previous exposure within 30 days)
2
(b) Occurrence of thrombocytopenia >10 days of initial heparin 
administration or unknown or <1 day (with previous exposure within 
30–100 days)
1
(c) Occurrence of thrombocytopenia at <4 days (without previous recent 
heparin exposure)
0
T3
Thrombosis or other 
sequelae
(a) New thrombosis, skin necrosis, acute systemic reaction following bolus 
heparin
2
(b) Progressive recurrent thrombosis, erythematous skin lesion, 
unconfirmed suspicion of thrombosis
1
(c) No other causes of thrombocytopenia 0
T4
Other cause of 
thrombocytopenia
(a) No other cause of thrombocytopenia 2
(b) Presence of other possible causes of thrombocytopenia 1
(c) Definitive other cause of thrombocytopenia is present 0
Low, 0–3; Moderate, 4–5; High, 6–8.
Table 1. Clinical assesement of Heparine induced thrombocytopenia (HIT) by use of modified 4T scoring system 
according to Lo and Warkentin [6].
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probability of HIT II. To confirm the diagnosis of HIT II, laboratory evidence of anti-heparin 
antibodies is needed. Anti-heparin antibodies may be confirmed in about half of the patients 
with clinically suspected HIT requiring laboratory investigation. The frequency of positive 
results depends on the clinical 4 T score and sensitivity and specificity of the test used [6–9].
4. Laboratory diagnostics
Laboratory investigation of HIT includes two categories of tests: immunologic assays for 
detecting circulating anti-PF4/heparin antibodies usually of IgG class and functional assays 
which detect antiplatelet antibodies capable to induce heparin-dependent platelet activation 
and thrombogenic potential (Table 2) [10–12].
In laboratory investigations of HIT II, anti-heparin-PF4 antibody tests are most commonly 
used in immunologic assays and serotonin-release assay (SRA) to determine anti-heparin 
antibody-induced platelet activation. In addition to, SRA heparin-induced platelet activation/
aggregation assay (HIPA) is used when the thrombogenic potential of the present antibodies 
should be determined or in vitro effectiveness of heparin, alternative should be estimated. 
Enzyme-immunologic (EIA) method and gel method are most commonly used for immu-
nologic assays. EIA is performed on a microtiter plate, and heparin-PF4 antigen complex is 
applied to the plate wells. Gel test is performed on gel-filled microcolonies, and the heparin-
PF4 complex is added into a microparticle suspension. These tests have a similar sensitivity 
(80–90%) and specificity (89–97%). The most important advantage of gel test (quick screening 
test) is a high negative predictive value (>95%) for the exclusion of HIT II. In the other group 
Method Sensitivity Specificity NPV PPV
Anti H-PF4 assays (antigen-antygody assays):
(a) Gel-columns-mycro-particle assay High Moderate High Low
(b) Lateral flow immunodiffudion assay-IgG High Moderate High Moderate
(c) EIA-IgG High Moderate High Moderate
Funtional assays:
(a) SRA-cr
(b) SRA-HPLC
(c)SRA-EIA
(d) HIPA
(e) HIMA
Low/moderate High High
H-PF4, heparin-platelet factor 4 complex; EIA, enzyme immuno assay; HPLC, high presure liquid cromatography; 
SRA, serotonin release assay; HIPA, heparin-induced platelet activation/aggregation; HIMA, heparin-induced platelet 
activation/multilate aggregation; NPV, negative predictive value; PPV, positive predictive value; H-PF4, heparin-platelet 
factor 4 complex.
Table 2. Methods for anti-heparin antibodies detection.
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of tests, heparin-induced platelet activation (HIPA), and serotonin-release assay (SRA) are the 
most commonly used tests. They have lower sensitivity, but higher specificity than the first 
group of tests. In addition to, EIA test result, OD value is also obtained. OD <1.000 indicates 
the presence of clinically significant antibodies and a high-risk of thromboembolic complica-
tions. OD ranging from 0.400 to 0.999 and low clinical 4T indicate low thrombogenic activity 
of the antibodies and subclinical HIT. Monitoring antibody titres using OD values is used 
in the preoperative preparation of patients with previously confirmed HIT II; the surgery 
in which heparin is given is performed after the antibody titter decreases or the test results 
become negative [14, 15].
To exclude other causes of thrombocytopenia, differential diagnosis should include pseudo 
thrombocytopenia (artifact), massive pulmonary embolism, disseminated intravascular coag-
ulation (DIK), sepsis, other drug-induced thrombocytopenia (e.g. by GP IIb/IIIa inhibitors), 
autoimmune or alloimmune thrombocytopenia, post-transfusion purpura, diabetic ketoaci-
dosis, and antiphospholipid syndrome with thrombocytopenia [16].
5. Treatment
Treatment of HIT patients is complex. In severely ill, heparin-treated patients who develop 
HIT II, there is often a misbalance of antithrombotic molecules including protein C, antithrom-
bine III, thrombomodulin, and others. If there is a lack of these regulators, their substitution 
may increase the anticoagulant effect of heparin alternatives [16]. Clinical assessment plays a 
key role not only in discerning the platelet count decrease caused by anti-heparin antibodies 
from the platelet count decrease caused by the underlying disease but also in the selection of 
anticoagulant agent [17].
According to the clinical practice guidelines on antithrombotic therapy and prevention of 
thrombosis, if there is laboratory evidence of anti-heparin antibodies, heparin should be dis-
continued immediately, and replaced by some other non-heparin anticoagulant. Most com-
monly used alternative anticoagulants are: direct thrombin inhibitors, heparinoids, and factor 
Xa inhibitors (Table 3) [17].
Hirudin is a direct inhibitor of thrombin and acts independently of cofactors such as anti-
thrombin. (19) Therefore, hirudin may be more effective in the presence of platelet-rich 
thrombi. Hirudin can also inhibit thrombin bound to fibrin or fibrin degradation products.
Direct thrombin inhibitors (DTI) Hirudin, lepirudin, bivaluridin argartoban
Heparionoides Danaparoid
Factor Xa inhibitors Fondaparinux
Direct oral anticoagulants(DOACs) Dabigatran, apixaban, rivaroxaban
Other Intravenous gamma globulins (IVIG)
Table 3. Alternative anticoagulants for treatment of heparin- induced thrombocytopenia type II (HIT II).
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Lepirudin is a recombinant hirudin and is a highly specific direct and irreversible inhibitor of 
thrombin. One molecule of lepirudin binds with one molecule of thrombin. Lepirudin is almost 
exclusively excreted by the kidneys and hence systemic clearance of lepirudin is dependent 
on the glomerular filtration rate. The drug should be avoided in hemodialysis patients and 
those with acute renal failure with creatinine clearance <15 ml min−1 (normally 120 ml min−1) or 
serum creatinine >528 μmol liter−1. The 2006 British Guidelines recommend lepirudin, recom-
binant protein, and direct thrombin inhibitor to be used as heparin alternatives [12].
Bivalirudin is a direct thrombin inhibitor and an analogue of the peptide fragment hirugen, which 
is a compound derived from hirudin. Unlike lepirudin, the binding of bivalirudin to thrombin is 
reversible. Bivalirudin binds specifically to the catalytic site and substrate-binding site of throm-
bin. The US Food and Drug Administration (FDA) has approved bivalirudin for use in patients 
undergoing coronary angioplasty with unstable angina who are also on aspirin therapy [18].
Argatroban is a direct competitive synthetic inhibitor of thrombin. It binds reversibly to the 
thrombin catalytic site and therefore, inhibits reactions that are catalyzed or induced by the 
presence of soluble and clot-bound thrombin. When given i.v. and is metabolized in the liver 
by cytochrome P450 enzymes it is 100% bioavailable. Unchanged drug is excreted in the urine 
(16%) and feces (14%). It is eliminated as its metabolite in the feces (65%), presumably through 
biliary secretion, and in the urine (22%) [17].
It should be taken into account that all non-heparin anticoagulants may also lead to anaphy-
lactic reaction and bleeding. However, unlike heparin, there is no known antidote for these 
agents and laboratory monitoring of their effects and antibody cross-reactivity is difficult 
(anti-Xa activity and ellagic time are not standard laboratory tests for hemostasis), in addition 
to the high price of the substance.
Danaparoid is a low molecular weight heparinoid. It is a mixture of dermatan sulfate, glycos-
aminoglycans, and chondroitin sulfate. A favorable outcome in 90% of patients with HIT is 
associated with the use of danaparoid. The main activity of danaparoid is against factor Xa, with 
the anti-Xa: the anti-IIa ratio of 22:1 resulting in inhibition of fibrin formation. There is a 10–20% 
cross-reactivity rate with HIT antibodies in vitro although it is less common in vivo. [18].
Coumarin agents (e.g. warfarin) are contraindicated in acute HIT II, because they increase 
the risk of microvascular thrombosis, necrosis, and gangrene. Replacing UFH with LWMH is 
also contraindicated in the treatment of HIT II due to the antibody cross-reactivity [12, 13, 18].
Most guidelines suggest the use of argatroban over other nonheparin anticoagulants in patients 
with HITT and renal insufficiency, and the use of bivalirudin over other nonheparin antico-
agulants or heparin plus antiplatelet agents in patients with acute HIT or subacute HIT who 
require urgent cardiac surgery (Grade 2C) [12, 18, 19].
Recently, the most commonly used agent has been fondaparinux, a synthetic and selective 
factor Xa inhibitor, which rarely causes anti-heparin antibody cross-reactivity. Clinical expe-
rience shows it has beneficial effects in the prevention of thromboembolic complications. The 
fondaparinux results are an important step in developing the recommendations for the use of 
alternative agents to heparin, although randomized studies are needed [20, 21].
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The use of oral direct thrombin inhibitors in the treatment of HIT II (dabigatran, rivaroxa-
ban, and apixaban) also holds promise. The effectiveness of rivaroxaban in HIT patients 
was assessed in several studies showing no cross-reactivity with anti-heparin antibodies. 
Moreover, there was no PF4 release from platelets, as opposed to enoxaparin-LWMH [22, 23]. 
HIT can be managed with danaparoid in post-cardiac surgery patients. However, in absence 
of any increase of platelet count after 3–5 days of danaparoid therapy and/or occurrence of 
a new thrombotic event, danaparoid cross-reactivity with heparin should be suspected and 
replaced with direct thrombin inhibitor [24].
There is a dozen of evidence that in some patients with severe HIT II refractory to standard 
treatment immediate and sustained respond could be achieved by the admission of intrave-
nous gamma globulin (IVIg), most probably mediated by inhibition of platelet activation [25].
According to the literature data, prophylactic platelet transfusions in thrombocytopenic HIT 
patients are contraindicated. Since spontaneous bleeding in HIT is rare, and platelet transfu-
sions may potentially increase the risk of thrombosis, their use is recommended in case of 
life-threatening bleeding. Contrary, there is not clear evidence suggested that platelet transfu-
sions should be avoided in a critically ill bleeding patient with HIT. [26].
In a couple of studies, platelet transfusion was administered prophylactically to prevent 
bleeding in post-surgery patients. These patients experienced no new thrombotic complica-
tion but expected post-transfusion platelet count increment was not achieved. Furthermore, 
previous deep venous thrombosis progressed after platelet transfusion and subsequently led 
to death in one patient [27].
6. Conclusion
HIT II is immunologically-induced, a life-threatening side effect of heparin therapy associ-
ated with thromboembolic complications. All patients receiving heparin are exposed to the 
development of anti-heparin antibodies, irrespective of the heparin dosage, type, and method 
of administration. HIT most commonly develops in intensive care patients, dialyzed patients, 
and cardiosurgical and orthopedic patients. Clinical assessment of the HIT probability using 
4T scoring system, systematic monitoring of platelet number in heparin-receiving patients, 
and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the 
final confirmation of the diagnosis, enable timely administration of direct non-heparin throm-
bin antagonists, and reduce mortality from thromboembolic complications.
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